This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2016 May 12;374(19):1807-9.

doi: 10.1056/NEJMp1601294.

Drug Regulation and Pricing--Can Regulators Influence Affordability?

Hans-Georg Eichler¹, Hugo Hurts¹, Karl Broich¹, Guido Rasi¹

Affiliations

Affiliation

¹ From the European Medicines Agency, London (H.-G.E., G.R.); European Medicines Agency Management Board, London (H.H., K.B.); Medical University of Vienna, Vienna (H.-G.E.); College ter Beoordeling van Geneesmiddelen, Utrecht, the Netherlands (H.H.); Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (K.B.); and the University of Rome Tor Vergata, Rome (G.R.).

PMID: 27168431
DOI: 10.1056/NEJMp1601294

Drug Regulation and Pricing--Can Regulators Influence Affordability?

Hans-Georg Eichler et al. N Engl J Med. 2016.

. 2016 May 12;374(19):1807-9.

doi: 10.1056/NEJMp1601294.

Authors

Hans-Georg Eichler¹, Hugo Hurts¹, Karl Broich¹, Guido Rasi¹

Affiliation

¹ From the European Medicines Agency, London (H.-G.E., G.R.); European Medicines Agency Management Board, London (H.H., K.B.); Medical University of Vienna, Vienna (H.-G.E.); College ter Beoordeling van Geneesmiddelen, Utrecht, the Netherlands (H.H.); Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (K.B.); and the University of Rome Tor Vergata, Rome (G.R.).

PMID: 27168431
DOI: 10.1056/NEJMp1601294

No abstract available

PubMed Disclaimer

Similar articles

The ongoing regulation of generic drugs.
Frank RG. Frank RG. N Engl J Med. 2007 Nov 15;357(20):1993-6. doi: 10.1056/NEJMp078193. N Engl J Med. 2007. PMID: 18003956 No abstract available.
A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
Feldman R, Wang C. Feldman R, et al. N Engl J Med. 2017 Apr 20;376(16):1499-1501. doi: 10.1056/NEJMp1700202. Epub 2017 Mar 1. N Engl J Med. 2017. PMID: 28248550 No abstract available.
Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
Zhao M, Wu J. Zhao M, et al. Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):311-320. doi: 10.1080/14737167.2017.1251318. Epub 2016 Nov 8. Expert Rev Pharmacoecon Outcomes Res. 2017. PMID: 27762144
[Competition and prices in the Mexican pharmaceutical market].
Molina-Salazar RE, González-Marín E, Carbajal-de Nova C. Molina-Salazar RE, et al. Salud Publica Mex. 2008;50 Suppl 4:S496-503. doi: 10.1590/s0036-36342008001000011. Salud Publica Mex. 2008. PMID: 19082261 Review. Spanish.
Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs.
Ablavsky G, Larrimore Ouellette L. Ablavsky G, et al. JAMA Intern Med. 2018 Feb 1;178(2):179-180. doi: 10.1001/jamainternmed.2017.7463. JAMA Intern Med. 2018. PMID: 29297039 Review. No abstract available.

See all similar articles

Cited by

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.
Gronde TV, Uyl-de Groot CA, Pieters T. Gronde TV, et al. PLoS One. 2017 Aug 16;12(8):e0182613. doi: 10.1371/journal.pone.0182613. eCollection 2017. PLoS One. 2017. PMID: 28813502 Free PMC article.
Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis.
Li DG, Najafzadeh M, Kesselheim AS, Mostaghimi A. Li DG, et al. BMJ. 2019 Jul 17;366:l4257. doi: 10.1136/bmj.l4257. BMJ. 2019. PMID: 31315833 Free PMC article.
Precision medicine and the changing role of regulatory agencies.
Breckenridge A, Eichler HG, Jarow JP. Breckenridge A, et al. Nat Rev Drug Discov. 2016 Dec;15(12):805-806. doi: 10.1038/nrd.2016.206. Epub 2016 Oct 14. Nat Rev Drug Discov. 2016. PMID: 27739512
The value of anticancer drugs - a regulatory view.
Pignatti F, Wilking U, Postmus D, Wilking N, Delgado J, Bergh J. Pignatti F, et al. Nat Rev Clin Oncol. 2022 Mar;19(3):207-215. doi: 10.1038/s41571-021-00584-z. Epub 2021 Dec 6. Nat Rev Clin Oncol. 2022. PMID: 34873312 Review.
Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice.
Maignen F, Osipenko L, Pinilla-Dominguez P, Crowe E. Maignen F, et al. Eur J Clin Pharmacol. 2017 Mar;73(3):297-305. doi: 10.1007/s00228-016-2174-2. Epub 2016 Dec 10. Eur J Clin Pharmacol. 2017. PMID: 27942759

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information